Improving daily COPD symptoms, as measured using the E-RS, with umeclidinium/vilanterol versus monotherapy: the EMAX trial
P. Jones (Brentford, Middlesex, United Kingdom), L. Bjermer (Lund, Sweden), C. Vogelmeier (Marburg, Germany), F. Maltais ( Québec City, QC, Canada), I. Naya (Brentford, Middlesex, United Kingdom), L. Tombs ( Uxbridge, Middlesex, United Kingdom), I. Boucot (Brentford, Middlesex, United Kingdom), T. Keeley (Uxbridge, Middlesex, United Kingdom), D. Lipson (Collegeville, PA, United States of America), C. Compton (Brentford, Middlesex, United Kingdom), E. Kerwin (Medford, OR, United States of America)
Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies
Session: COPD clinical trials: inhaled and oral therapies
Session type: Thematic Poster
Number: 2474
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Jones (Brentford, Middlesex, United Kingdom), L. Bjermer (Lund, Sweden), C. Vogelmeier (Marburg, Germany), F. Maltais ( Québec City, QC, Canada), I. Naya (Brentford, Middlesex, United Kingdom), L. Tombs ( Uxbridge, Middlesex, United Kingdom), I. Boucot (Brentford, Middlesex, United Kingdom), T. Keeley (Uxbridge, Middlesex, United Kingdom), D. Lipson (Collegeville, PA, United States of America), C. Compton (Brentford, Middlesex, United Kingdom), E. Kerwin (Medford, OR, United States of America). Improving daily COPD symptoms, as measured using the E-RS, with umeclidinium/vilanterol versus monotherapy: the EMAX trial. 2474
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Indacaterol once-daily improves symptom control in COPD patients: a 52-week evaluation vs placebo (pbo) and formoterol (for) Source: Annual Congress 2009 - New bronchodilators Year: 2009
48-week administration of olodaterol QD via Respimat® vs placebo and formoterol BID in patients with COPD: Pooled safety analysis Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013
Pharmacokinetic (PK) analysis of fluticasone furoate (FF), umeclidinium (UMEC) and vilanterol (VI) following triple therapy at two UMEC doses in healthy subjects Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014
Efficacy and safety of umeclidinium/vilanterol compared with umeclidinium or tiotropium in COPD Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013
Lung function efficacy of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: Two 48-week studies Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
Pharmacokinetic (PK) analysis of fluticasone furoate (FF), umeclidinium (UMEC) and vilanterol (VI) following triple therapy in healthy subjects Source: International Congress 2014 – Asthma and COPD management Year: 2014
Once-daily QVA149 improves dyspnoea and health status compared with tiotropium plus formoterol in patients without ICS use: A post-hoc analysis of the QUANTIFY study Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015
Indacaterol once-daily improves day and night-time symptom control in COPD patients: a 26-week study versus placebo and tiotropium Source: Annual Congress 2009 - New bronchodilators Year: 2009
Symptomatic benefit of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: Combined analysis from two 48-week studies Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
Formoterol turbuhaler compared with salbutamol as reliever medication in asthma: a worldwide, randomised, effectiveness trial (RELIEF Study) Source: Eur Respir J 2002; 20: Suppl. 38, 44s Year: 2002
Healthcare resource use following addition of montelukast to budesonide compared to doubling the dose of budesonide in patients with inadequately controlled asthma (COMPACT trial) Source: Eur Respir J 2004; 24: Suppl. 48, 126s Year: 2004
LATE-BREAKING ABSTRACT: Efficacy and safety of once-daily (OD) fluticasone furoate (FF) in patients with persistent asthma: A 24-week randomised trial Source: Annual Congress 2012 - Animal models of asthma and COPD and late-breaking abstracts on RCT in asthma and COPD Year: 2012
LATE-BREAKING ABSTRACT: Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: The SHINE study Source: Annual Congress 2012 - New drug targets and pre-clinical models for respiratory diseases Year: 2012
LATE-BREAKING ABSTRACT: Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol/fluticasone combination (SFC) in patients with COPD: the LANTERN study Source: International Congress 2014 – Latest insights in airway diseases Year: 2014
Improving COPD symptoms with umeclidinium/vilanterol and impact of baseline disease severity: the EMAX trial Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019
Once-daily indacaterol/glycopyrronium (IND/GLY) reduces use of rescue medication versus twice-daily salmeterol/fluticasone (SFC) in patients with moderate-to-very severe COPD: results from the FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting beta2 -agonist/inhaled corticosteroid (LABA/ICS): The ILLUMINATE study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013
LATE-BREAKING ABSTRACT: Once-daily QVA149 significantly improves lung function and symptoms compared to twice-daily fluticasone/salmeterol in COPD patients: The ILLUMINATE study Source: Annual Congress 2012 - Exacerbations of asthma and COPD: assessment, impact and novel treatments Year: 2012
Umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014
Once-daily QVA149 provides the same efficacy as the free combination of its monocomponents indacaterol and glycopyrronium: The BEACON study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013